Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)
Publication
, Journal Article
Published in: Investigational New Drugs
December 1, 2011
Duke Scholars
Published In
Investigational New Drugs
DOI
EISSN
1573-0646
ISSN
0167-6997
Publication Date
December 1, 2011
Volume
29
Issue
6
Start / End Page
1517 / 1518
Related Subject Headings
- Oncology & Carcinogenesis
- 3214 Pharmacology and pharmaceutical sciences
- 3211 Oncology and carcinogenesis
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). (2011). Investigational New Drugs, 29(6), 1517–1518. https://doi.org/10.1007/s10637-010-9502-7
“Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8).” Investigational New Drugs 29, no. 6 (December 1, 2011): 1517–18. https://doi.org/10.1007/s10637-010-9502-7.
Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs. 2011 Dec 1;29(6):1517–8.
“Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8).” Investigational New Drugs, vol. 29, no. 6, Dec. 2011, pp. 1517–18. Scopus, doi:10.1007/s10637-010-9502-7.
Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs. 2011 Dec 1;29(6):1517–1518.
Published In
Investigational New Drugs
DOI
EISSN
1573-0646
ISSN
0167-6997
Publication Date
December 1, 2011
Volume
29
Issue
6
Start / End Page
1517 / 1518
Related Subject Headings
- Oncology & Carcinogenesis
- 3214 Pharmacology and pharmaceutical sciences
- 3211 Oncology and carcinogenesis
- 1115 Pharmacology and Pharmaceutical Sciences